Literature DB >> 22897822

Lung cancer stem cells: tumor biology and clinical implications.

Fariz Nurwidya1, Akiko Murakami, Fumiyuki Takahashi, Kazuhisa Takahashi.   

Abstract

The concept of cancer stem cells (CSC) has drawn great attention from researchers in both molecular and clinical fields as has brought a new perspective to the way we manage cancer. CSC have several characteristics that are shared by the properties of normal stem cells, such as differentiation, self-renewal and homeostatic control. However, CSC have the capacity to both divide and expand the CSC pool and to differentiate into heterogeneous non-tumorigenic cancer cells. Even more, CSC have an inherent high resistance to chemotherapeutic agents that leads to recurrence and poor long-term survival, especially in lung cancer patients. CSC-targeting agents are now undergoing in vitro and in vivo studies, some of which have provided promising results for further clinical studies setting. In this article we review the concept of CSC from the perspective of tumor biology, including the origin of CSC and its biomarkers. As lung cancer is the leading cause of cancer-related deaths worldwide, we focus on the properties and clinical implications of lung CSC.
© 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22897822     DOI: 10.1111/j.1743-7563.2012.01550.x

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  5 in total

1.  CD44 silencing decreases the expression of stem cell-related factors induced by transforming growth factor β1 and tumor necrosis factor α in lung cancer: Preliminary findings.

Authors:  Fariz Nurwidya; Fumiyuki Takahashi; Motoyasu Kato; Hario Baskoro; Moulid Hidayat; Aditya Wirawan; Kazuhisa Takahashi
Journal:  Bosn J Basic Med Sci       Date:  2017-08-20       Impact factor: 3.363

2.  Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer.

Authors:  J Jacob Wamsley; Manish Kumar; David F Allison; Sheena H Clift; Caitlyn M Holzknecht; Szymon J Szymura; Stephen A Hoang; Xiaojiang Xu; Christopher A Moskaluk; David R Jones; Stefan Bekiranov; Marty W Mayo
Journal:  Cancer Res       Date:  2014-11-28       Impact factor: 12.701

Review 3.  Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy.

Authors:  Bin Bao; Aamir Ahmad; Asfar S Azmi; Shadan Ali; Fazlul H Sarkar
Journal:  Curr Protoc Pharmacol       Date:  2013-06

4.  Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity.

Authors:  Jiliang Feng; Dawei Zhao; Fudong Lv; Zhongyu Yuan
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

5.  Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.

Authors:  Alessia Noto; Claudia De Vitis; Giuseppe Roscilli; Luigi Fattore; Debora Malpicci; Emanuele Marra; Laura Luberto; Antonio D'Andrilli; Pierpaolo Coluccia; Maria Rosaria Giovagnoli; Nicola Normanno; Luigi Ruco; Luigi Aurisicchio; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2013-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.